Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02267083 · ClinicalTrials.gov registry record · Phase 2

Efficacy and Safety Study of GPX-150 to Treat Soft Tissue Sarcoma

A Phase 2 study of Soft Tissue Sarcoma, sponsored by Gem Pharmaceuticals.

Completed
Registry status
Phase 2
Development phase
22
Enrollment target
4
Study locations

NCT02267083 is a Phase 2 study of Soft Tissue Sarcoma that has completed, run by Gem Pharmaceuticals. The registered enrollment target is 22 participants, below the 79-participant average among 55 other Soft Tissue Sarcoma trials with a reported enrollment target (72% lower). The trial reports 4 study locations across 4 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02267083, a Phase 2 study of Soft Tissue Sarcoma, has completed, sponsored by Gem Pharmaceuticals.

COMPLETED
Registry status
Phase 2
Development phase
22 participants
Enrollment target
4
Study locations

Study Summary

This study will assess the safety and efficacy of GPX-150 administered intravenously every 3 weeks in the treatment of patients with soft tissue sarcoma.

Conditions Studied

Soft Tissue Sarcoma

Interventions

  • DRUG GPX-150 for Injection

Study Locations (4)

Illinois

  • Northwestern University - Chicago

Iowa

  • University of Iowa Holden Comprehensive Cancer Center - Iowa City

Missouri

  • Washington University School of Medicine - St Louis

Pennsylvania

  • Penn State Milton S Hershey Medical Center - Hershey

Trial Details

FieldValue
Enrollment Target 22 participants
Start Date 2015-01-07
Est. Completion 2016-08-18
Phase Phase 2

Sponsor

Gem Pharmaceuticals

4 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02267083

The ClinicalTrials.gov registry entry for NCT02267083 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 79-participant average among 55 other Soft Tissue Sarcoma trials with a reported enrollment target (72% lower). The listed sponsor is Gem Pharmaceuticals, which has 4 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Soft Tissue Sarcoma appearing as the primary indexed condition, and to 1 intervention - of which GPX-150 for Injection is the first listed.

NCT02267083 reports 4 study locations spanning 4 distinct geographic areas - top geographies include Illinois, Iowa, Missouri.

Frequently Asked Questions

What is clinical trial NCT02267083 about?

NCT02267083 is a clinical study titled "Efficacy and Safety Study of GPX-150 to Treat Soft Tissue Sarcoma". This study will assess the safety and efficacy of GPX-150 administered intravenously every 3 weeks in the treatment of patients with soft tissue sarcoma.

What is the current status of trial NCT02267083?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 22 participants. The study started on 2015-01-07. Estimated completion is 2016-08-18.

What conditions does trial NCT02267083 study?

This clinical trial studies the following conditions: Soft Tissue Sarcoma.

What interventions are being tested in trial NCT02267083?

The interventions under investigation include: GPX-150 for Injection (DRUG).

Who is sponsoring clinical trial NCT02267083?

This trial is sponsored by Gem Pharmaceuticals, which has 4 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02267083 being conducted?

This trial has 4 study locations across Illinois, Iowa, Missouri, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Soft Tissue Sarcoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Soft Tissue Sarcoma

All registered trials for this condition

Illinois

All trials with a study site in Illinois

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.